Europe Biopsy Devices Market Size & Forecast 2026–2034

The Europe Biopsy Devices Market is expected to grow steadily in the coming years as healthcare systems place greater emphasis on early disease detection and accurate diagnosis. According to Renub Research, the market is projected to expand from US$ 713.32 Million in 2025 to US$ 1,206.16 Million by 2034, registering a compound annual growth rate (CAGR) of 6.01% between 2026 and 2034.

Download Sample Report

Biopsy devices play a critical role in modern diagnostics, particularly in detecting cancers and other chronic diseases. With the rising prevalence of cancer across Europe, increasing investments in healthcare infrastructure, and a strong push for preventive screening programs, the demand for advanced biopsy technologies is growing rapidly.

At the same time, continuous technological advancements—such as minimally invasive biopsy techniques and image-guided procedures—are improving diagnostic accuracy while reducing patient discomfort. These innovations are making biopsy devices an essential component of modern healthcare systems across the European region.

Europe Biopsy Devices Market Outlook

Biopsy devices are specialized medical tools designed to collect small samples of tissue or cells from the body for examination. These samples are analyzed under a microscope to detect abnormal cells, infections, or cancer.

Several types of biopsy devices are widely used in clinical settings, including:

Needle biopsy devices

Vacuum-assisted biopsy systems

Core biopsy needles

Biopsy forceps

These devices enable healthcare professionals to conduct minimally invasive diagnostic procedures, offering faster recovery times, minimal patient discomfort, and highly accurate results.

Biopsy procedures are commonly used to diagnose diseases affecting organs such as:

Breast

Lung

Liver

Prostate

Skin

Across Europe, the demand for biopsy devices is increasing as healthcare providers focus on early diagnosis and preventive care. Many European governments actively promote screening programs aimed at identifying diseases—particularly cancer—at earlier stages when treatment outcomes are significantly better.

In addition, Europe benefits from well-developed healthcare infrastructure, modern hospitals, and highly trained medical professionals. This advanced healthcare ecosystem has enabled the rapid adoption of innovative diagnostic tools, including next-generation biopsy devices.

Technological innovations are also enhancing diagnostic precision. Modern biopsy systems integrate imaging technologies, automation, and improved needle designs to provide accurate tissue sampling while minimizing risks for patients.

Growth Drivers of the Europe Biopsy Devices Market

Rising Prevalence of Cancer and Chronic Diseases

One of the most significant factors driving the Europe biopsy devices market is the increasing incidence of cancer and chronic illnesses.

According to the European Cancer Information System, approximately 2.74 million new cancer cases were reported in Europe in 2022, and this number is projected to rise to around 3.24 million cases by 2040.

The most common types of cancer include:

Breast cancer

Prostate cancer

Lung cancer

Colorectal cancer

Together, these cancers account for nearly half of all diagnosed cases across Europe.

The aging population is a key contributor to the rising prevalence of cancer. As individuals age, the risk of developing cancer and other chronic conditions increases significantly. In 2022 alone, 1.29 million cancer-related deaths were recorded in Europe, highlighting the urgent need for early detection and improved diagnostic tools.

Biopsy procedures remain the gold standard for confirming cancer diagnoses. Accurate tissue sampling allows healthcare providers to determine the presence, type, and severity of cancer, enabling doctors to develop personalized treatment plans.

Government-supported screening initiatives and growing public awareness of preventive healthcare are also encouraging individuals to undergo early diagnostic tests. As a result, the demand for reliable biopsy devices continues to expand across the region.

Technological Advancements in Minimally Invasive Biopsy Techniques

Technological innovation is another key factor driving the adoption of biopsy devices in Europe.

Modern biopsy technologies are designed to be minimally invasive, allowing healthcare providers to obtain tissue samples with high precision while minimizing patient discomfort and recovery time.

Some of the most advanced biopsy technologies include:

Image-guided biopsy systems

Vacuum-assisted biopsy devices

Automated biopsy needles

Image-guided biopsy procedures use imaging technologies such as CT scans, ultrasound, or MRI to precisely locate abnormal tissue. This improves diagnostic accuracy and significantly reduces complications.

Vacuum-assisted biopsy systems are particularly effective for breast cancer diagnosis, enabling physicians to collect multiple tissue samples through a single insertion.

Medical device manufacturers are also heavily investing in research and development to improve the safety, efficiency, and accuracy of biopsy procedures.

For example, in October 2025, Olympus Corporation introduced SecureFlex, a single-use fine needle biopsy device designed to enhance precision and reduce contamination risks. The device became commercially available across Europe and Japan in late 2025.

Such technological developments continue to improve clinical outcomes and strengthen the overall biopsy devices market.

Strong Healthcare Infrastructure and Government Screening Programs

Europe is known for its advanced healthcare systems and strong public health initiatives. Many European countries provide universal healthcare services that emphasize preventive care and early diagnosis.

Government-supported screening programs are widely implemented for several cancers, including:

Breast cancer

Cervical cancer

Colorectal cancer

These screening initiatives have significantly increased the number of diagnostic procedures performed across hospitals and clinics.

In February 2026, several EU4Health initiatives—including PRAISE-U, SOLACE, and TOGAS—introduced new protocols and pilot programs aimed at expanding cancer screening across EU member states.

Such initiatives are expected to improve early cancer detection rates and increase the demand for biopsy procedures across Europe.

Additionally, hospitals and diagnostic centers across the region are equipped with advanced imaging technologies and diagnostic equipment. This infrastructure allows healthcare professionals to perform highly accurate biopsy procedures with improved patient safety.

As public awareness regarding preventive healthcare continues to grow, more individuals are undergoing routine health screenings, further driving the adoption of biopsy devices.

Challenges in the Europe Biopsy Devices Market

High Cost of Advanced Biopsy Devices and Procedures

Despite strong market growth, the high cost associated with advanced biopsy technologies remains a challenge.

Modern biopsy systems—particularly those integrated with imaging technologies—require significant investment. Hospitals must allocate substantial budgets for purchasing equipment, maintaining devices, and training medical staff.

Smaller healthcare facilities and diagnostic centers may face financial constraints when adopting advanced biopsy technologies. These costs could potentially limit market expansion in certain regions.

Although many European countries provide government-funded healthcare services, cost management remains a critical concern for healthcare providers.

Risk of Procedure-Related Complications and Patient Concerns

Another challenge for the biopsy devices market is patient hesitation due to perceived risks associated with biopsy procedures.

Some patients fear complications such as:

Pain

Bleeding

Tissue damage

Infection

Although modern biopsy techniques are generally safe and minimally invasive, anxiety about medical procedures can discourage individuals from undergoing diagnostic testing.

Additionally, the lack of trained professionals or improper handling of biopsy equipment may increase the risk of complications in certain cases.

Improving patient education, enhancing physician training, and adopting safer technologies will be essential to addressing these concerns and supporting market growth.

Europe Needle-Based Biopsy Devices Market

Needle-based biopsy devices represent one of the most widely used segments within the Europe biopsy devices market.

These devices include:

Fine needle aspiration (FNA) systems

Core needle biopsy devices

Needle-based biopsies are preferred due to several advantages:

Minimally invasive procedures

Lower costs compared to surgical biopsies

Faster recovery times

High diagnostic accuracy

The growing incidence of cancers such as breast, lung, and prostate cancer is increasing the demand for these devices.

Furthermore, continuous improvements in needle design are enhancing safety and efficiency, making these procedures more reliable for healthcare providers.

Europe CT Scan Biopsy Market

CT-guided biopsy procedures are becoming increasingly popular in Europe.

Computed tomography (CT) imaging enables physicians to precisely locate tumors or abnormal tissues within organs such as:

Lungs

Liver

Abdomen

This imaging technique helps doctors collect tissue samples from difficult-to-reach areas while minimizing the risk of complications.

As the number of cancer cases continues to rise, healthcare facilities across Europe are increasingly relying on CT-guided biopsy procedures to improve diagnostic accuracy.

Europe MRI-Guided Biopsy Devices Market

MRI-guided biopsy is gaining traction due to its exceptional ability to visualize soft tissues.

This technology is particularly useful for diagnosing cancers affecting:

Breast

Prostate

Brain

MRI-guided biopsy systems allow physicians to detect abnormalities that may not be visible through other imaging methods.

The adoption of this technology is increasing across advanced healthcare facilities in Europe, where precision diagnostics and patient safety remain top priorities.

Europe Biopsy Diagnostic Laboratories Devices Market

Diagnostic laboratories play a critical role in the biopsy process by analyzing collected tissue samples.

Advanced laboratory equipment helps pathologists identify diseases such as cancer, infections, and inflammatory conditions with high accuracy.

As the number of biopsy procedures increases, laboratories across Europe are investing in sophisticated diagnostic technologies to enhance efficiency and accuracy.

Government initiatives promoting early disease detection are further strengthening this segment of the market.

Europe Biopsy Devices Hospitals and Clinics Market

Hospitals and clinics represent the largest end-user segment for biopsy devices in Europe.

These healthcare facilities are equipped with advanced medical technologies and trained professionals capable of performing complex diagnostic procedures.

The increasing prevalence of chronic diseases and cancer has significantly increased the number of biopsy procedures conducted in hospitals and clinics.

Healthcare providers are continuously investing in advanced diagnostic equipment to improve patient outcomes and reduce diagnostic errors.

Country Insights: Key Markets in Europe

Several countries across Europe are contributing significantly to the growth of the biopsy devices market.

France has a well-developed healthcare system and strong national cancer screening programs, leading to increased biopsy procedures.

The United Kingdom is experiencing growing demand for biopsy devices as the National Health Service (NHS) promotes early cancer detection through public health initiatives.

Germany remains a major hub for medical technology innovation, with hospitals widely adopting advanced biopsy devices.

Russia is also witnessing market growth as healthcare modernization initiatives improve access to diagnostic technologies across major cities and medical centers.

Competitive Landscape

The Europe biopsy devices market includes several major global companies specializing in medical diagnostics and biotechnology.

Key players include:

Becton, Dickinson and Company

Thermo Fisher Scientific Inc

Bio-Rad Laboratories

Exact Sciences (Genomic Health)

Biocept

Roche Diagnostics

Myriad Genetics Inc

Qiagen

NeoGenomics Laboratories

Quest Diagnostics Inc

These companies focus on product innovation, research and development, strategic partnerships, and global expansion to strengthen their market presence.

Final Thoughts

The Europe Biopsy Devices Market is entering a phase of steady and sustainable growth. Rising cancer prevalence, aging populations, and increasing emphasis on early disease detection are driving the demand for advanced biopsy technologies across the region.

With strong healthcare infrastructure, ongoing government screening initiatives, and rapid technological innovation, biopsy devices are becoming indispensable tools in modern diagnostics.

As medical technology continues to evolve and awareness of preventive healthcare increases, the biopsy devices market in Europe is expected to expand significantly in the coming years—improving diagnostic accuracy, enabling early treatment, and ultimately saving lives.